Literature DB >> 3346774

Diabetes mellitus associated with cystic fibrosis.

S M Finkelstein1, C L Wielinski, G R Elliott, W J Warwick, J Barbosa, S C Wu, D J Klein.   

Abstract

The prevalence of overt diabetes mellitus and carbohydrate intolerance was studied in 448 patients with cystic fibrosis (CF). Insulin-dependent diabetes (IDDM) developed in 7.6% of patients (13 male and 21 female). Survival was significantly lower (P less than 0.01) in the IDDM-CF group, with fewer than 25% surviving to age 30 years, whereas nearly 60% of the nondiabetic CF population reached this age. A significant deterioration in CF clinical status, based on NIH score, became apparent 2 years before onset of overt IDDM (P less than 0.05 at 2 years prior, P less than 0.01 at IDDM diagnosis). Total glycosylated hemoglobin (HbA1) was significantly (P less than 0.001) higher for the total CF population (7.3% +/- 1.2%) than for the general non-CF population (6.5% +/- 0.7%), and in the IDDM-CF group (P less than 0.05) compared with normoglycemic CF control patients. Female patients had a higher mean HbA1 after 12 years of age than their male counterparts did (P less than 0.02). HBA1 did not predict the development of IDDM, but there was a weak inverse relationship between HbA1 and both NIH clinical score (r = -0.41, P less than 0.02) and standard pulmonary function tests (forced vital capacity, r = -0.25, P less than 0.01) in the general CF population. Therefore, impaired carbohydrate tolerance in CF is associated with progressive clinical deterioration.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3346774     DOI: 10.1016/s0022-3476(88)80315-9

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  49 in total

Review 1.  Understanding cystic-fibrosis-related diabetes: best thought of as insulin deficiency?

Authors:  Lee Dobson; Christopher D Sheldon; Andrew T Hattersley
Journal:  J R Soc Med       Date:  2004       Impact factor: 5.344

2.  Oral glucose tolerance testing in cystic fibrosis: correlations with clinical parameters and glycosylated haemoglobin determinations.

Authors:  J De Schepper; I Dab; M P Derde; H Loeb
Journal:  Eur J Pediatr       Date:  1991-04       Impact factor: 3.183

Review 3.  Cystic fibrosis: yesterday, today and tomorrow.

Authors:  R Dinwiddie
Journal:  J R Soc Med       Date:  1991       Impact factor: 5.344

4.  Glucose tolerance in cystic fibrosis.

Authors:  S Lanng; B Thorsteinsson; G Erichsen; J Nerup; C Koch
Journal:  Arch Dis Child       Date:  1991-05       Impact factor: 3.791

Review 5.  Diagnosis, screening, and management of cystic fibrosis-related diabetes.

Authors:  Antoinette Moran
Journal:  Curr Diab Rep       Date:  2002-04       Impact factor: 4.810

6.  Hyperglycemia impedes lung bacterial clearance in a murine model of cystic fibrosis-related diabetes.

Authors:  William R Hunt; Susu M Zughaier; Dana E Guentert; Melissa A Shenep; Michael Koval; Nael A McCarty; Jason M Hansen
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2013-10-04       Impact factor: 5.464

7.  Reduced pancreatic insulin release and reduced peripheral insulin sensitivity contribute to hyperglycaemia in cystic fibrosis.

Authors:  R W Holl; E Heinze; A Wolf; M Rank; W M Teller
Journal:  Eur J Pediatr       Date:  1995-05       Impact factor: 3.183

8.  Glucose tolerance in patients with cystic fibrosis: five year prospective study.

Authors:  S Lanng; A Hansen; B Thorsteinsson; J Nerup; C Koch
Journal:  BMJ       Date:  1995-09-09

9.  Cystic fibrosis-related diabetes: from CFTR dysfunction to oxidative stress.

Authors:  Thierry Ntimbane; Blandine Comte; Geneviève Mailhot; Yves Berthiaume; Vincent Poitout; Marc Prentki; Rémi Rabasa-Lhoret; Emile Levy
Journal:  Clin Biochem Rev       Date:  2009-11

10.  Sex disparities in effects of cystic fibrosis-related diabetes on clinical outcomes: a matched study.

Authors:  R J Miller; H D Tildesley; P G Wilcox; H Zhang; S H Kreisman
Journal:  Can Respir J       Date:  2008-09       Impact factor: 2.409

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.